N/A N=937 Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology
Chronic Heart Failure
Primary: Number of All Causes Deaths and (Unplanned) Hospitalizations — 1.46; 1.30 Events — p==0.80
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=6 A Study to Measure the Degree and Effectiveness of the Various vSculpt Operating Modes
Sexual Dysfunction · Stress Incontinence
Primary: Change in Blood Flow as Measured by Temperature Change in the Genitalia Using Thermography Technology — -0.5; 1.8; -0.3; -0.2 Celsius degree
Phase 4 N=68 Niacin, N-3 Fatty Acids and Insulin Resistance
Metabolic Syndrome · Hypertriglyceridemia
Primary: Serum TG — 233; 157; 176; 156 mg/dl
Phase 2 N=34 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Colorectal Cancer · Colorectal Carcinoma · Colorectal Adenocarcinoma
Primary: Number of Participants With Grade 1-5 Adverse Events — 4; 12; 4; 13 Participants
Phase 2 N=25 Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
Urinary Incontinence · Stress · Urination Disorders
Primary: Rate of Product-related, Biopsy Procedure-related, and Injection Procedure-related Adverse Events — 0; 2; 0; 12 events
N/A N=66 Clinical Assessment of a Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lens
Myopia
Primary: Mean Distance Visual Acuity (logMAR) With Study Lenses — -0.11; -0.13; -0.12; -0.13 logMAR
Phase 2 N=78 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
Acute Leukemia of Ambiguous Lineage · B Acute Lymphoblastic Leukemia · Mixed Phenotype Acute Leukemia
Primary: Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement…
Phase 3 N=277 Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
Atopic Dermatitis
Primary: At Least 75% Reduction in Eczema Area and Severity Index (EASI75) From Week 0 to Week 16 — 64.2; 50.5 Percentage of responders — p=0.018
N/A N=98 TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR
Tricuspid Valve Insufficiency
Primary: Number of Participants With Echocardiographic Tricuspid Regurgitation Reduction at Least 1 Grade — 71 Participants
N/A N=486 Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
Plaque Psoriasis
Primary: Mean Change From Baseline in Percent Body Surface Area (BSA) Score at Month 4 — 28.1; 29.21; -6.79; -6.38 Percent BSA — p=0.35
Phase 2 N=79 NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Non-small Cell Lung Cancer Stage III
Primary: Grade ≥3 Pneumonitis (CTCAE v4.0) up to 6 Months Post-radiotherapy — 71 Participants
N/A N=33 Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
Phase 4 N=9 Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score for 28-joint Counts (DAS28) — 5.7; 4.3 score on a scale
Phase 2 N=294 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.3; 14.1; 7.4 months — p=0.227
Phase 2 N=103 A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
ALK-positive Advanced NSCLC
Primary: Confirmed Objective Response Rate (ORR) Using RECIST v1.1 as Assessed by the Independent Review Committee (IRC) — 26.2 percentage of participants — p=0.0763